Table 3.
Multivariate and univariate analyses of factors associated with HBeAg seroconversion at 24 weeks posttreatment
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| Odd ratio | 95% confidence interval | P value | Odd ratio | 95% confidence interval | P value | |
| Sex (male) | 0.810 | (0.241–2.651) | 0.715 | |||
| Age (years) | 0.896 | (0.818–0.981) | 0.018 | 0.687 | (0.384–0.850) | 0.040 |
| ALT (U/L) × ULN at baseline | 1.315 | (0.977–1.768) | 0.071 | 1.660 | (1.097–2.875) | 0.041 |
| AST (U/L) × ULN at baseline | 1.298 | (0.849–1.501) | 0.087 | |||
| Baseline HBV DNA ≤ 30,000,000 copies/mL copies/mL | 1.636 | (0.542–4.937) | 0.382 | |||
| Baseline HBV RNA ≤ 200,000 copies/mL | 3.818 | (1.228–12.871) | 0.021 | 1.841 | (1.175–3.708) | 0.008 |
| Baseline HBsAg ≤8000 IU/mL | 6.001 | (1.787–20.150) | 0.004 | 3.791 | (1.969–25.358) | 0.003 |
| HBV DNA ≤ 200,000 copies/mL at week 12 | 3.429 | (0.969–12.131) | 0.056 | |||
| HBV RNA ≤ 3000 copies/mL at week 12 | 5.357 | (1.605–17.879) | 0.006 | 12.458 | (3.969–80.494) | 0.039 |
| HBsAg ≤4000 IU/mL at week 12 | 7.363 | (2.150–25.223) | 0.001 | |||
| HBV DNA ≤ 30,000 copies/mL at week 24 | 12.681 | (1.783–60.873) | 0.012 | |||
| HBV RNA ≤ 1000 copies/mL at week 24 | 6.500 | (1.915–22.051) | 0.003 | |||
| HBsAg ≤2000 IU/mL at week 24 | 7.519 | (2.232–25.316) | 0.001 | 3.297 | (1.346–21.391) | 0.031 |
ALT alanine aminotransferase, AST aspartate aminotransferase, HBsAg hepatitis B surface antigen, HBV DNA hepatitis B deoxyribonucleic acid, HBV RNA hepatitis B ribonucleic acid